We screened 1662 studies on Gastrointestinal Cancer this month. These are the most important.
Gemcitabine and capecitabine recommended as new adjuvant therapy option in pancreatic cancer
- ASCO guidelines for potentially curable pancreatic cancer updated on the basis of new clinical trial results.
Nivolumab shows promise in advanced esophageal SCC
- There is no defined treatment strategy for patients with esophageal cancer who are refractory or intolerant to standard therapies.
- In this phase 2 study, nivolumab showed promising antitumor activity with an acceptable safety profile.
HCC: segmental radioembolization tops chemoembolization
- This retrospective study demonstrated a number of advantages of segmental radioembolization over chemoembolization for localized HCC, including better complete response rates, local tumor control, and PFS, with similar toxicity profiles.
Other recent Vitals: